GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures
GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.
Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 million people worldwide. During this period, both deaths and disabilities due to CVD have been on the rise globally. 1 As cardiac cases continue to rise, there is an urgent need for tools that improve the efficiency of cardiac cath and EP procedures. Efficient diagnosis and therapy are key elements of addressing the growing demand for care.
'AltiX AI.i is built on more than two decades of experience, leadership and innovation in invasive cardiology to enhance cath labs and EP procedures and empower clinicians to deliver the best possible outcomes,' said Jyoti Gera, CEO, CardioVascular & Interventional Solutions, GE HealthCare. 'By automating routine tasks and streamlining workflow, AltiX AI.i allows clinicians to focus on what truly matters – providing exceptional patient care.'
Mac-Lab for cardiac catheterization
The AltiX AI.i edition of Mac-Lab recording system combines functionality with workflow optimization. Clinicians can adopt this solution to elevate the cath lab user experience. The integration of the diastolic pressure ratio (dPR) algorithm allows users to easily perform this measurement, and builds on its ability to capture diastolic hyperemia-free ratio (DFR) measurements. These measurements are used to assess the severity of coronary artery disease. Mac-Lab provides optional Cath Lab Command Center access with a large display, advanced video and layouts, and customized documentation tools for a better user experience.
CardioLab for EP procedures
For EP procedures, the AltiX AI.i edition of CardioLab offers improved signal quality for visualization of physiological signals using the Prucka™ 3 digital amplifier. Prucka 3 is a solution that reduces environmental noise, maintains high signal fidelity and provides new signal-filtering capabilities for more advanced evaluations. 2 The latest CardioLab edition showcases GE HealthCare's collaboration with Volta Medical, Volta Interface, which utilizes PruckaStream to share real-time data to inform its Volta AF-Xplorer™ decision support system. The feature is designed to support clinicians with real-time assessments using artificial intelligence (AI) to automatically assess areas believed to initiate or maintain atrial fibrillation drivers. For an optimal visual experience, users can also harness the EP Command Center.
ComboLab for a comprehensive solution
ComboLab seamlessly integrates EP and hemodynamic recording into a single system, offering versatile functionality for both cath lab procedures and EP exams. ComboLab merges the best of Mac-Lab and CardioLab to give clinicians a comprehensive solution to manage various cardiac procedures in one location. Its familiar interface and workflow ease the learning curve, and its capability to document and export diagnostic data helps capture more information at the point of care.
'The introduction of AltiX AI.i reinforces our commitment to advancing cardiac care. These improved solutions are designed to enhance diagnostic and therapeutic capabilities, which are crucial for diagnosing and treating various heart conditions,' said Arnaud Marie, General Manager, Interventional Solutions, GE HealthCare. 'This launch is an important step in our ongoing mission to equip healthcare providers with interventional solutions that evolve alongside their needs.'
In recognition of its innovation and leadership, GE HealthCare was recently honored by Frost & Sullivan as the 2024 Company of the Year in the Global Next-Generation EP Labs Industry. This prestigious award highlights GE HealthCare's commitment to growth and excellence in the field.
GE HealthCare will showcase the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab at the European Heart Rhythm Association (EHRA) 2025 annual congress taking place on March 30 - April 1 in Vienna, Austria and Heart Rhythm Society (HRS) 2025 annual meeting on April 24 - April 27 in San Diego. AltiX AI.i is available for order in the United States and will launch in global markets later this year. * Consult with your GE HealthCare sales representative for more information on the availability of AltiX AI.i in your country. For more information, visit: https://www.gehealthcare.com/products/invasive-cardiology.
* AltiX AI.i is 510(k) cleared and CE mark pending.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
1 Roth, G, Mensah, G, Johnson, C. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. JACC. 2020 Dec, 76 (25) 2982–3021.
https://doi.org/10.1016/j.jacc.2020.11.010
2 GE HealthCare Data on File
Eric Tatro
GE HealthCare
+1 312 459 6140
[email protected]
SOURCE: GE HealthCare Technologies Inc.
Copyright Business Wire 2025.
PUB: 03/17/2025 09:01 AM/DISC: 03/17/2025 09:02 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
HPE and Commvault Strengthen Strategic Partnership to Deliver Industry-Leading Cyber Resilience Solutions
LAS VEGAS--(BUSINESS WIRE)-- HPE Discover 2025 – HPE (NYSE: HPE) and Commvault (NASDAQ: CVLT), a leader in cyber resilience and data protection solutions for the hybrid cloud, today announced an expanded strategic partnership to combat the increasing challenges of cyber threats and data loss. Building on a longstanding collaboration across GreenLake cloud and the Commvault Cloud platform, the enhanced partnership deepens technology integration and joint go-to-market to deliver advanced cyber resilience, data protection, and disaster recovery capabilities for enterprise hybrid cloud environments. In addition to its own robust offerings, Commvault will integrate and offer HPE Zerto Software to support Commvault Cloud customers in managing demanding virtualized on-premises and cloud workloads. Leveraging sophisticated Continuous Data Protection technology, HPE Zerto delivers near-zero recovery point objectives (RPOs) and recovery time objectives (RTOs) ensuring operational resilience. Adding HPE Zerto capabilities to Commvault Cloud gives customers added flexibility to tailor their cyber resilience and disaster recovery strategy to meet the needs of their business. 'The expanded partnership with Commvault underscores our shared commitment to solve the most complex data protection challenges that enterprises face,' said Fidelma Russo, executive vice president and general manager of Hybrid Cloud and CTO at HPE. 'Our combined innovations set a new standard for data resilience, helping customers navigate a rapidly evolving threat landscape.' Sanjay Mirchandani, president and CEO of Commvault, added, 'This partnership builds on the long history of co-innovation between Commvault and HPE. At a time when data is more valuable and vulnerable than ever, our collaboration is empowering customers to keep their business continuous by advancing their resilience and protection of hybrid workloads.' The companies are also introducing enhanced integration between the HPE storage and data protection and Commvault Cloud portfolios to safeguard sensitive data, protect against ransomware, and ensure seamless recovery from disruptions. For HPE customers seeking a turnkey cloud-based solution that provides robust protection of hybrid, cloud-native, and SaaS workloads, Commvault Cloud SaaS is an integral part of the joint portfolio that spans from edge-to-cloud and source-to-target. Addressing Cyber Threats with Enhanced Solutions Ransomware, AI-driven attacks, and other cyber threats are compelling enterprises to prioritize cyber resilience as a critical component of their data protection strategies. As part of the expanded partnership, HPE and Commvault intend to introduce key joint innovations to neutralize the evolving threat landscape: Ultra Resilience: The combination of HPE Alletra Storage MP B10000 with built-in ransomware detection and snapshot immutability, HPE Cyber Resilience Vault with air-gapped protection, and Commvault Cloud AI-enhanced anomaly detection and threat scanning provides unmatched resilience and peace of mind. Fast, Clean Recovery: The integration of HPE Alletra Storage MP X10000 featuring data protection accelerator nodes with Commvault Cloud enables enterprises to return to operation safely and rapidly after an incident. It brings together blazing fast storage, typical 20-to-1 data reduction, and the broadest protection across hybrid cloud workloads. Geographic Protection: Commvault Cloud seamlessly orchestrates simultaneous snapshots and local backups for two synchronously replicated HPE Alletra Storage MP B10000 arrays, located in different geographical regions. This integration significantly streamlines data protection workflows and delivers unparalleled recoverability for critical enterprise data. Building on an Established Portfolio This partnership is based on deep collaboration and innovation to help enterprises modernize their data protection strategies, including integrations with HPE StoreOnce backup appliances and HPE Storage Tape solutions for highly cost-effective, long-term data retention, as well as advanced image-based protection for virtualized environments through HPE Morpheus VM Essentials Software. Together, HPE and Commvault are delivering an expansive suite of solutions that tackle data protection and cyber resilience challenges head-on, at every stage of the enterprise data lifecycle. The expertise of the two companies helps customers minimize risk, modernize infrastructure, and achieve operational continuity in the most complex hybrid and multicloud environments. Additional Resources HPE Zerto Software Commvault Cloud HPE Alletra Storage MP B10000 HPE Alletra Storage MP X10000 About HPE HPE (NYSE: HPE) is a global technology leader focused on developing intelligent solutions that allow customers to capture, analyze, and act upon data seamlessly. The company innovates across networking, hybrid cloud, and AI to help customers develop new business models, engage in new ways, and increase operational performance. For more information, visit: About Commvault Commvault (NASDAQ: CVLT) is the gold standard in cyber resilience, helping more than 100,000 organizations keep data safe and businesses resilient and moving forward. Today, Commvault offers the only cyber resilience platform that combines the best data security and rapid recovery at enterprise scale across any workload, anywhere—at the lowest TCO.
Yahoo
an hour ago
- Yahoo
Tesla's Latest Wall Street Target Comes with a Caveat
UBS raised its Tesla (NASDAQ:TSLA) price target to $235 from $190 after Tesla's first robotaxi pilot rolled out in Austin, Texas. Yet it stuck with its Sell rating, arguing that the stock's sky-high valuation already prices in autonomy and future-tech dreams. The bank pegs a 2.3 million-vehicle robotaxi fleet by 2040 to generate about $200 billion in annual revenuevaluing that business alone at $99 per sharebut says those optimistic assumptions are baked into Tesla's $1.14 trillion market cap and 181 P/E ratio, leaving little margin for execution missteps. While Elon Musk touts autonomy and humanoid robots as the next big growth drivers, UBS warns of regulatory hurdles, manufacturing scale-up risks and the time needed to turn pilot programs into profitable services, maintaining a cautious stance despite the long-term promise of a driverless future. Why It Matters: With autonomy hype fueling much of Tesla's valuation, any delay or hiccup in robotaxi or robotics rollouts could trigger a sharp repricing. Tesla's 12-month price targets have dipped to about $290 on average, roughly 17% below today's $350-ish trading level. Bulls still see room up toward $500 if robotaxis and AI breakthroughs pan out, but the skeptics land at an eye-popping $19underscoring how split the Street is on execution risk. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the 'Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC ('DolCas'), a New Jersey-based developer and manufacturer of clinically studied nutraceutical ingredients. Cosmos Health is set to commence production in the United States at GMP-certified (Good Manufacturing Practice) facilities, marking a significant milestone in the Company's operational expansion. This move not only mitigates tariff exposure and cross-border logistical risks but also enhances production control beyond its existing European footprint, positioning Cosmos to scale efficiently in the global healthcare market. The agreement strengthens Cosmos Health's position in the premium nutraceuticals space and supports its broader strategy to expand its portfolio with scientifically backed, high-efficacy ingredients, while also leveraging DolCas's expertise in clinically validated formulations and vertically integrated manufacturing. K. Gnaneshwar Rao, CEO at DolCas Biotech, commented: 'We are thrilled to partner with Cosmos and are eager to build on this collaboration with a wide range of innovative products that will benefit both companies. Cosmos, under the visionary leadership of CEO Greg Siokas, has built an impressive portfolio of brands and products. His forward-thinking approach aligns perfectly with our values and ambitions. We see this as the beginning of a strong, strategic partnership and look forward to supporting Cosmos' continued growth in the United States and globally.' Greg Siokas, CEO of Cosmos Health, stated: 'We are proud to reach this important milestone as we commence production in the United States through our agreement with DolCas Biotech, a partner widely recognized for its commitment to quality and innovation. This strategic move strengthens our supply chain, enhances production oversight, and positions Cosmos for scalable global growth. It also reduces exposure to tariff-related risks, adding resilience amid shifting trade dynamics.' About DolCas Biotech LLCDolCas Biotech LLC is a U.S.-based developer and marketer of branded, science-backed nutraceutical ingredients, founded in 2007 as an extension of Orcas Naturals founded in 1993. Its portfolio includes, among others, clinically supported products such as Curcugen® (turmeric), Ginfort® (ginger), Morikol® (marine collagen), and TruOliv® (olive polyphenols). Through its dedicated manufacturing arm in India, the company maintains full vertical integration and strict control over ingredient quality. Its facilities are GMP-certified, FDA-registered, and UL-audited, underscoring a strong commitment to regulatory excellence and product integrity. About Cosmos Health Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:BDG Communicationscosm@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
